

Endorsement and Maintenance Team
Partnership for Quality Measurement
PQMSupport@battelle.org

July 2, 2026

Re: Support for Endorsement of the Rate of Annual Kidney Health Evaluation Among Adults with Diabetes and/or Hypertension (CBEID 5611e)

Dear Members of the Partnership for Quality Measurement Endorsement and Maintenance Committee,

The American Kidney Fund is writing to express our strong support for endorsement of the measure, *Rate of Annual Kidney Health Evaluation Among Adults with Diabetes and/or Hypertension* (CBEID 5611e). This measure addresses a well-documented gap in the use of an annual kidney health evaluation for adults at high risk for chronic kidney disease (CKD) due to its two leading causes, diabetes and hypertension.

CKD is a an underrecognized public health crisis affecting approximately 37 million adults in the United States. Because kidney disease often progresses silently and presents few signs or symptoms until advanced stages, many individuals remain undiagnosed until irreversible damage has occurred. Adults with diabetes and hypertension are at a particularly high risk for CKD and represent populations for whom timely screening and early intervention are critically important.

Measure performance is based on the percentage of patients aged 18–85 years with a diagnosis of diabetes and/or hypertension who received both an eGFR and uACR during the measurement period. The measure reflects current clinical guideline recommendations by Kidney Disease Improving Global Outcomes (KDIGO), the American Heart Association (AHA) and American College of Cardiology (ACC), the National Kidney Foundation (NKF) and the American Diabetes Association (ADA). Performance of the eGFR and uACR in these populations is the foundation of earlier identification of CKD, more accurate staging of disease, and timely implementation of interventions that can slow disease progression and reduce complications.

Importantly, endorsement of this measure would help drive greater accountability and consistency in kidney health screening practices across healthcare systems. Increased uptake of evidence-based kidney health evaluation will improve screening, encourage diagnosis, support gap closure in CKD detection and treatment, and lower long-term healthcare costs associated with cardiovascular complications and kidney failure.

For these reasons, the American Kidney Fund strongly supports endorsement of CBEID 5611e. We appreciate the Partnership for Quality Measurement's commitment to advancing high-quality, evidence-based care.

Thank you for your consideration.

Sincerely,



Michael Spigler, MCHES
Chief Program Officer